Monopar Therapeutics
corporate_fare Company Profile
Monopar Therapeutics (NASDAQ:MNPR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for MNPR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MNPR spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Monopar Posts $6.2M Q3 Loss, $129.4M Cash, NDA Submission Weeks Away
- Monopar Q3 Loss Widens to $6.2M as R&D Spend Jumps; $129.4M Cash Lasts to March 2028
- Monopar Q2 2026: Cash Runway Through 2027, Rolling NDA Submission Underway
- Six Insiders Adopt 10b5-1 Trading Plans for Up to 91,889 Shares
- Monopar Posts Wider Q2 Loss, Insider Trading Plans Adopted Amid NDA Push
Financial Snapshot
Short Interest & Short Volume
8.80 days to coverFINRA reported short interest of 1,103,516 shares in MNPR as of the October 30, 2026 settlement, a 2.2% decrease from the prior period — about 8.8 days to cover at its recent average daily volume. On November 20, 2026, 74.1% of MNPR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.